Navigation Links
Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
Date:3/20/2008

SUNRISE, Fla., March 20 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) will report financial results for the year ended December 31, 2007 after the close of the market on Thursday, March 27, 2008. The Company has scheduled a conference call for Thursday, March 27, 2008 at 4:30 p.m. Eastern to discuss these results.

Interested parties can access the call by dialing (877) 858-9308 or (706) 643-0580, or can listen via a live Internet web cast, which can be found at http://www.bioheartinc.com. A replay of the call is available via webcast at http://www.bioheartinc.com for 30 days or by playback at (800) 642-1687 or (706) 645-9291 through March 29, 2008. Please use conference id #: 39978839 for the replay.

About Bioheart, Inc.:

Bioheart, Inc. is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from the patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose cell treatment for acute heart damage, and MyoCell II with SDF-1(TM), a therapy utilizing autologous cells genetically modified to express additional growth factors.

MyoCell and MyoCell II with SDF-1 are registered trademarks of Bioheart, Inc.

Contact: William Kline Lytham Partners, LLC

Chief Financial Officer Joe Diaz

Nicholas Burke Joe Dorame

VP - Financial Operations Robert Blum

(954) 835-1500 (602) 889-9700


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
2. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
3. Vion Reports 2007 Fourth Quarter and Year-End Results
4. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
5. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
6. Warner Chilcott Reports the Death of Its Director James Andress
7. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Unigene Restates Policy on Analyst Reports
10. NPS Pharmaceuticals Reports 2007 Financial Results
11. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... in Vilnius, Lithuania, announced today that they have entered into a multiyear collaboration ... to provide CRISPR researchers with additional tools for gene editing across all applications. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Wound Market with the addition of its newest module, US Hemostats & Sealants. ... for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalindâ„¢, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):